Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease

Atopic dermatitis (AD) is a chronically relapsing skin inflammatory disorder characterized by perivascular infiltration of immunoglobulin-E (IgE), T-lymphocytes and mast cells. The key pathophysiological factors causing this disease are immunological disorders and the compromised epidermal barrier i...

Full description

Bibliographic Details
Published in:Colloids and Surfaces B: Biointerfaces
Main Author: Shao M.; Hussain Z.; Thu H.E.; Khan S.; Katas H.; Ahmed T.A.; Tripathy M.; Leng J.; Qin H.-L.; Bukhari S.N.A.
Format: Review
Language:English
Published: Elsevier B.V. 2016
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984782982&doi=10.1016%2fj.colsurfb.2016.08.027&partnerID=40&md5=e43f0f68b3e235edab3f80d0995db84e
id 2-s2.0-84984782982
spelling 2-s2.0-84984782982
Shao M.; Hussain Z.; Thu H.E.; Khan S.; Katas H.; Ahmed T.A.; Tripathy M.; Leng J.; Qin H.-L.; Bukhari S.N.A.
Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease
2016
Colloids and Surfaces B: Biointerfaces
147

10.1016/j.colsurfb.2016.08.027
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984782982&doi=10.1016%2fj.colsurfb.2016.08.027&partnerID=40&md5=e43f0f68b3e235edab3f80d0995db84e
Atopic dermatitis (AD) is a chronically relapsing skin inflammatory disorder characterized by perivascular infiltration of immunoglobulin-E (IgE), T-lymphocytes and mast cells. The key pathophysiological factors causing this disease are immunological disorders and the compromised epidermal barrier integrity. Pruritus, intense itching, psychological stress, deprived physical and mental performance and sleep disturbance are the hallmark features of this dermatological complication. Preventive interventions which include educational programs, avoidance of allergens, exclusive care towards skin, and the rational selection of therapeutic regimen play key roles in the treatment of dermatosis. In last two decades, it is evident from a plethora of studies that scientific focus is being driven from conventional therapies to the advanced nanocarrier-based regimen for an effective management of AD. These nanocarriers which include polymeric nanoparticles (NPs), hydrogel NPs, liposomes, ethosomes, solid lipid nanoparticles (SLNs) and nanoemulsion, provide efficient roles for the target specific delivery of the therapeutic payload. The success of these targeted therapies is due to their pharmaceutical versatility, longer retention time at the target site, avoiding off-target effects and preventing premature degradation of the incorporated drugs. The present review was therefore aimed to summarise convincing evidence for the therapeutic superiority of advanced nanocarrier-mediated strategies over the conventional therapies used in the treatment of AD. © 2016 Elsevier B.V.
Elsevier B.V.
9277765
English
Review

author Shao M.; Hussain Z.; Thu H.E.; Khan S.; Katas H.; Ahmed T.A.; Tripathy M.; Leng J.; Qin H.-L.; Bukhari S.N.A.
spellingShingle Shao M.; Hussain Z.; Thu H.E.; Khan S.; Katas H.; Ahmed T.A.; Tripathy M.; Leng J.; Qin H.-L.; Bukhari S.N.A.
Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease
author_facet Shao M.; Hussain Z.; Thu H.E.; Khan S.; Katas H.; Ahmed T.A.; Tripathy M.; Leng J.; Qin H.-L.; Bukhari S.N.A.
author_sort Shao M.; Hussain Z.; Thu H.E.; Khan S.; Katas H.; Ahmed T.A.; Tripathy M.; Leng J.; Qin H.-L.; Bukhari S.N.A.
title Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease
title_short Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease
title_full Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease
title_fullStr Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease
title_full_unstemmed Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease
title_sort Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease
publishDate 2016
container_title Colloids and Surfaces B: Biointerfaces
container_volume 147
container_issue
doi_str_mv 10.1016/j.colsurfb.2016.08.027
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984782982&doi=10.1016%2fj.colsurfb.2016.08.027&partnerID=40&md5=e43f0f68b3e235edab3f80d0995db84e
description Atopic dermatitis (AD) is a chronically relapsing skin inflammatory disorder characterized by perivascular infiltration of immunoglobulin-E (IgE), T-lymphocytes and mast cells. The key pathophysiological factors causing this disease are immunological disorders and the compromised epidermal barrier integrity. Pruritus, intense itching, psychological stress, deprived physical and mental performance and sleep disturbance are the hallmark features of this dermatological complication. Preventive interventions which include educational programs, avoidance of allergens, exclusive care towards skin, and the rational selection of therapeutic regimen play key roles in the treatment of dermatosis. In last two decades, it is evident from a plethora of studies that scientific focus is being driven from conventional therapies to the advanced nanocarrier-based regimen for an effective management of AD. These nanocarriers which include polymeric nanoparticles (NPs), hydrogel NPs, liposomes, ethosomes, solid lipid nanoparticles (SLNs) and nanoemulsion, provide efficient roles for the target specific delivery of the therapeutic payload. The success of these targeted therapies is due to their pharmaceutical versatility, longer retention time at the target site, avoiding off-target effects and preventing premature degradation of the incorporated drugs. The present review was therefore aimed to summarise convincing evidence for the therapeutic superiority of advanced nanocarrier-mediated strategies over the conventional therapies used in the treatment of AD. © 2016 Elsevier B.V.
publisher Elsevier B.V.
issn 9277765
language English
format Review
accesstype
record_format scopus
collection Scopus
_version_ 1818940563526778880